Alliancebernstein L.P. Sells 11 Shares of Haemonetics Corporation (HAE)

Alliancebernstein L.P. lowered its stake in Haemonetics Corporation (NYSE:HAE) by 0.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 81,390 shares of the medical instruments supplier’s stock after selling 11 shares during the period. Alliancebernstein L.P. owned approximately 0.16% of Haemonetics Corporation worth $3,302,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the company. Ameritas Investment Partners Inc. acquired a new stake in shares of Haemonetics Corporation during the first quarter valued at about $179,000. State of Alaska Department of Revenue increased its stake in shares of Haemonetics Corporation by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 5,740 shares of the medical instruments supplier’s stock valued at $232,000 after buying an additional 130 shares in the last quarter. Kirr Marbach & Co. LLC IN increased its stake in shares of Haemonetics Corporation by 1.1% in the first quarter. Kirr Marbach & Co. LLC IN now owns 7,230 shares of the medical instruments supplier’s stock valued at $293,000 after buying an additional 80 shares in the last quarter. Stevens Capital Management LP increased its stake in shares of Haemonetics Corporation by 61.9% in the first quarter. Stevens Capital Management LP now owns 8,830 shares of the medical instruments supplier’s stock valued at $358,000 after buying an additional 3,375 shares in the last quarter. Finally, Karp Capital Management Corp acquired a new stake in shares of Haemonetics Corporation during the first quarter valued at about $377,000.

Shares of Haemonetics Corporation (NYSE:HAE) opened at 40.25 on Tuesday. The firm’s market cap is $2.11 billion. Haemonetics Corporation has a 12-month low of $29.17 and a 12-month high of $43.62. The firm’s 50-day moving average is $40.75 and its 200-day moving average is $40.12.

Haemonetics Corporation (NYSE:HAE) last announced its quarterly earnings results on Monday, May 8th. The medical instruments supplier reported $0.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.02. Haemonetics Corporation had a negative net margin of 2.96% and a positive return on equity of 10.66%. The firm had revenue of $228.10 million during the quarter, compared to analysts’ expectations of $215.06 million. During the same period in the prior year, the company posted $0.37 EPS. The company’s revenue was down 5.9% on a year-over-year basis. Analysts predict that Haemonetics Corporation will post $1.60 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Alliancebernstein L.P. Sells 11 Shares of Haemonetics Corporation (HAE)” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://sportsperspectives.com/2017/07/18/alliancebernstein-l-p-has-3-30-million-position-in-haemonetics-corporation-hae-updated.html.

Several research firms have recently weighed in on HAE. Jefferies Group LLC reaffirmed a “buy” rating and set a $42.00 price objective on shares of Haemonetics Corporation in a report on Monday, May 8th. Zacks Investment Research lowered shares of Haemonetics Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, May 9th. TheStreet lowered shares of Haemonetics Corporation from a “b-” rating to a “c” rating in a report on Monday, May 8th. JMP Securities raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 price target for the company in a report on Thursday, July 13th. Finally, BidaskClub lowered shares of Haemonetics Corporation from a “hold” rating to a “sell” rating in a report on Friday, June 23rd. Two analysts have rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company’s stock. Haemonetics Corporation currently has a consensus rating of “Hold” and an average price target of $37.86.

In other news, Director Ronald Merriman sold 17,471 shares of the stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $40.33, for a total transaction of $704,605.43. Following the completion of the sale, the director now directly owns 24,925 shares in the company, valued at $1,005,225.25. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.20% of the company’s stock.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply